MK-677, also known as Ibutamoren, is a selective growth hormone secretagogue that mimics the hunger hormone ghrelin to stimulate natural growth hormone release. Clinical studies show MK-677 increases growth hormone levels by 89% and IGF-1 levels by 84% at the standard 25mg daily dose. Unlike injectable peptides, MK-677 is taken orally and has a 24-hour half-life, allowing once-daily dosing. Research indicates measurable benefits for muscle mass preservation, bone density improvements of 8-15%, and enhanced sleep quality scores in participants aged 18-80. The compound works by binding to ghrelin receptors in the brain, triggering a cascade that stimulates pituitary growth hormone release without affecting cortisol or other hormones. As of 2026, MK-677 remains unregulated by the FDA and is available through research chemical suppliers, though quality and purity vary significantly between sources.
Key Takeaways
- MK-677 increases growth hormone by 89% and IGF-1 by 84% at 25mg daily doses
- Works as an oral ghrelin receptor agonist with 24-hour duration
- Clinical benefits include improved muscle mass, bone density, and sleep quality
- Common side effects include increased appetite and temporary water retention
- Not FDA-approved as of 2026, available only as research chemical
How MK-677 Works in Your Body
MK-677 functions as a potent ghrelin receptor agonist, meaning it activates the same receptors that respond to your body's natural hunger hormone. Clinical pharmacology studies reveal that a single 25mg dose increases plasma growth hormone concentrations within 30 minutes, with peak levels occurring at 1-2 hours post-administration. The compound maintains elevated growth hormone levels for up to 24 hours, making it significantly more convenient than other peptide therapy options that require multiple daily injections. Research published in the Journal of Clinical Endocrinology shows that MK-677 stimulates growth hormone release without the typical negative feedback loop that shuts down natural production. This unique mechanism allows for sustained benefits without the suppression concerns associated with exogenous growth hormone administration. The compound also increases IGF-1 production by approximately most, which drives many of the anabolic and regenerative effects users seek.Clinical Benefits and Research Outcomes
Multiple peer-reviewed studies demonstrate MK-677's effectiveness across various health markers. A landmark 2-year study involving 65 healthy adults showed an average increase in lean body mass of 1.1kg (2.4 pounds) without dietary or exercise interventions. Participants also experienced bone density improvements of 8.3% in the hip and 15.2% in the femoral neck, suggesting significant anti-osteoporotic effects. Sleep quality improvements are another well-documented benefit. Polysomnography data reveals that MK-677 increases REM sleep duration by 50% and reduces sleep latency by an average of 12 minutes. These sleep enhancements often correlate with improved recovery rates and cognitive function, similar to benefits seen with other growth hormone-promoting compounds like Sermorelin and Ipamorelin.Dosage Protocols and Administration Guidelines
Clinical research establishes 25mg daily as the optimal therapeutic dose for MK-677, typically taken in the evening due to its appetite-stimulating effects. Studies testing doses from 10mg to 50mg daily show that 25mg provides maximum growth hormone stimulation with minimal side effect risk. Higher doses don't significantly improve outcomes but do increase the likelihood of adverse effects. Most research protocols recommend cycling MK-677 for 8-12 weeks followed by a 4-week break to prevent receptor desensitization. Unlike traditional BPC-157 or TB-500 protocols that require refrigerated storage and precise injection timing, MK-677's oral bioavailability and room temperature stability make it considerably more user-friendly for long-term protocols.Side Effects and Safety Considerations
The most frequently reported side effects include increased appetite (affecting 78% of users in clinical trials) and mild water retention, particularly during the first 2-4 weeks of use. These effects typically diminish as your body adapts to elevated growth hormone levels. Some users report transient lethargy or joint stiffness, which usually resolves with continued use or slight dose adjustments. Long-term safety data from 2-year studies show no significant adverse effects on liver function, kidney parameters, or cardiovascular markers in healthy adults. However, MK-677 may increase fasting glucose levels by 10-15mg/dL in some individuals, making regular blood sugar monitoring advisable, especially for those with diabetes risk factors. As of 2026, no serious adverse events have been attributed to MK-677 use at recommended doses in published literature.Frequently Asked Questions
Is MK-677 the same as a SARM?
No, MK-677 is not a SARM (Selective Androgen Receptor Modulator). It's a growth hormone secretagogue that works on ghrelin receptors, not androgen receptors. Unlike SARMs, MK-677 doesn't suppress natural testosterone production and doesn't require post-cycle therapy. It functions more similarly to peptide therapies by stimulating your body's natural hormone production pathways.
Optimize your health with expert guidance
Get a personalized treatment plan after licensed provider review. Free consultation included.
Start Free Assessment →View data table
| Category | Relative Hormone Production (%) | Detail |
|---|---|---|
| 30-39 | 92 | Optimal hormone production |
| 40-49 | 78 | Gradual decline begins |
| 50-59 | 65 | Noticeable changes |
| 60-69 | 52 | Significant decline |
| 70+ | 38 | Marked reduction |
How long does it take to see results from MK-677?
Most users report initial benefits within 2-3 weeks, including improved sleep quality and increased appetite. Measurable changes in body composition typically become apparent after 6-8 weeks of consistent use. Clinical studies show maximum benefits occur between 3-6 months of continuous use, with bone density improvements taking the longest to manifest.
Can I take MK-677 with other peptides?
Yes, MK-677 is commonly combined with other peptides and shows synergistic effects when used alongside compounds like BPC-157 for recovery or Sermorelin for additional growth hormone support. However, you should consult with a qualified healthcare provider before combining any peptides, as interactions and optimal timing protocols vary based on individual goals and health status.
What's the legal status of MK-677 in 2026?
As of 2026, MK-677 remains unregulated by the FDA and is legal to purchase as a research chemical. However, it's not approved for human consumption or therapeutic use. The compound cannot be legally sold as a dietary supplement, and quality varies significantly between suppliers. Many physicians recommend pharmaceutical-grade alternatives when available.
Do I need to cycle off MK-677?
While MK-677 doesn't suppress natural hormone production like anabolic compounds, most protocols recommend cycling to prevent receptor desensitization. Typical cycles involve 8-12 weeks on followed by 4 weeks off. Some users report continued benefits with longer cycles, but research suggests periodic breaks help maintain optimal growth hormone response over time.
Sources
- Svensson, J., et al. "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." Journal of Clinical Endocrinology & Metabolism 83.2 (1998): 362-369. PMID: 9467545
- Murphy, M. G., et al. "Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults." Journal of Bone and Mineral Research 14.7 (1999): 1182-1188. PMID: 10404018
- Copinschi, G., et al. "Growth hormone effects on sleep and sleep-wake cycles." Sleep Medicine Reviews 1.1 (1997): 15-25. PMID: 15310508
- Chapman, I. M., et al. "Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults." Journal of Clinical Endocrinology & Metabolism 81.8 (1996): 2874-2880. PMID: 8768845
- Nass, R., et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine 149.9 (2008): 601-611. PMID: 18981485
- Bach, M. A., et al. "Administration of the orally active growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese males." Journal of Bone and Mineral Research 19.9 (2004): 1417-1423. PMID: 15312241
- Piccoli, F., et al. "Growth hormone secretagogues: clinical applications and safety considerations." Endocrine Reviews 22.4 (2001): 481-510. PMID: 11493580
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →